Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors

详细信息    查看全文

• 作者：P. Jiménez-Fonseca ; A. Carmona-Bayonas ; E. Martín-Pérez…
• 关键词：Gastroenteropancreatic neuroendocrine tumors (GEP ; NETs) ; Health ; related quality of life (HRQoL) ; Peptide receptor radionuclide therapy (PRRT) ; Quality of life (QoL) ; Questionnaires ; Surgery ; Locoregional therapy ; Somatostatin analogs (SSA) ; Chemotherapy ; Targeted therapy
• 刊名：Cancer and Metastasis Reviews
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：34
• 期：3
• 页码：381-400
• 全文大小：721 KB
• 参考文献：1.Yao, J. C., Hassan, M., Phan, A., et al. (2008). One hundred years after “carcinoid- epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the united states. Journal of Clinical Oncology, 26(18), 3063-072.PubMed
  2.Beaumont, J. L., Cella, D., Phan, A. T., Choi, S., Liu, Z., & Yao, J. C. (2012). Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas, 41(3), 461-66.PubMed
  3.Larsson, G., Sjoden, P. O., Oberg, K., Eriksson, B., & von Essen, L. (2001). Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours. Acta Oncologica, 40(7), 825-31.PubMed
  4.US Department of Health and Human Services. (2006). Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health and Quality of Life Outcomes, 4, 79.
  5.Redeker, N. S., Lev, E. L., & Ruggiero, J. (2000). Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. Scholarly Inquiry for Nursing Practice, 14(4), 275-90. discussion 291-.PubMed
  6.Cella, D. (1998). Factors influencing quality of life in cancer patients: anemia and fatigue. Seminars in Oncology, 25(3 Suppl 7), 43-6.PubMed
  7.Coates, A., Gebski, V., Bishop, J. F., et al. (1987). Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. New England Journal of Medicine, 317(24), 1490-495.PubMed
  8.Ganz, P. A., Lee, J. J., & Siau, J. (1991). Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer, 67(12), 3131-135.PubMed
  9.Haugland, T., Vatn, M. H., Veenstra, M., Wahl, A. K., & Natvig, G. K. (2009). Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population. Quality of Life Research, 18(6), 719-26.PubMed
  10.Claringbold, P. G., Brayshaw, P. A., Price, R. A., & Turner, J. H. (2011). Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 38(2), 302-11.PubMed
  11.Raymond, E., Dahan, L., Raoul, J. L., et al. (2011). Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine, 364(6), 501-13.PubMed
  12.Rinke, A., Muller, H. H., Schade-Brittinger, C., et al. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology, 27(28), 4656-663.PubMed
  13.Teunissen, J. J., Kwekkeboom, D. J., & Krenning, E. P. (2004). Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. Journal of Clinical Oncology, 22(13), 2724-729.PubMed
  14.Kalinowski, M., Dressler, M., Konig, A., et al. (2009). Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion, 79(3), 137-42.PubMed
  15.Frilling, A., Weber, F., Saner, F., et al. (2006). Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery, 140(6), 967-68.
  16.Bushnell, D. L., Jr., O’Dorisio, T. M., O’Dorisio, M. S., et al. (2010). 90Y-edotreotide for metastatic carcinoid refractory to octreotide. Journal of Clinical Oncology, 28(10), 1652-659.PubMed
  17.Zuetenhorst, J. M., Valdes Olmos, R. A., Muller, M., Hoefnagel, C. A., & Taal, B. G. (2004). Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours. Endocrine-Related Cancer, 11(3), 553-61.PubMed
  18.Bajetta, E., Procopio, G., Catena, L., et al. (2006). Lanreotide autogel every 6?weeks compared with lanreotide microparticles every 3?weeks in patients with well differentiated neuroendocrine tumors: a phase III study. Cancer, 107(10), 2474-481.PubMed
  19.Ruszniewski, P., Ish-Shalom, S., Wymenga, M., et al. (2004). Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology, 80(4), 244-51.PubMed
  20.Cwikla, J. B., Sankowski, A., Seklecka, N., et al. (2010). Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Annals of Oncology, 21(4), 787-94.PubMed
  21.Martin-Richard, M., Massuti, B., Pineda, E., et al. (2013). Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, singl
• 作者单位：P. Jiménez-Fonseca (1)
  A. Carmona-Bayonas (2)
  E. Martín-Pérez (3)
  G. Crespo (4)
  R. Serrano (5)
  M. Llanos (6)
  C. Villabona (7)
  R. García-Carbonero (8)
  J. Aller (9)
  J. Capdevila (10)
  E. Grande (11)
  On behalf of the Spanish Neuroendocrine Tumor Group (GETNE)
  
  1. Department of Medical Oncology, Central Asturias University Hospital, C/ Avenida de Roma sn, Oviedo, 33011, Asturias, Spain
  2. Department of Hematology and Medical Oncology, Morales Meseguer University Hospital, Murcia, Spain
  3. Department of General Surgery, La Princesa University Hospital, Madrid, Spain
  4. Department of Medical Oncology, Burgos University Hospital, Burgos, Spain
  5. Department of Medical Oncology, Reina Sofia University Hospital, Córdoba, Spain
  6. Department of Medical Oncology, Canarias University Hospital, Tenerife, Spain
  7. Department of Endocrinology, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain
  8. Department of Medical Oncology, Virgen del Rocio University Hospital, Instituto de Biomedicina de Sevilla (IBIS) [Universidad de Sevilla, CSIC, HUVR], Center affiliated with the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Sevilla, Spain
  9. Department of Endocrinology, Puerta de Hierro University Hospital, Madrid, Spain
  10. Department of Medical Oncology, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Center affiliated with the Red Temática de Investigación Cooperativa en Cancer (RTICC), Instituto Carlos III, Spanish Ministry of Science and Innovation, Barcelona, Spain
  11. Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Cancer Research
  
• 出版者：Springer Netherlands
• ISSN：1573-7233

文摘

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare neoplasms capable of producing hormones. The development of new treatments has improved progression-free survival, albeit with increased toxicity. Health-related quality of life (HRQoL) has become an important endpoint in clinical research to evaluate patients-well-being in such a contradictory scenario. In this review, we examine key reported outcomes across clinical studies exploring HRQoL in patients with GEP-NETs. We have conducted a review of the literature using PubMed, The Cochrane Library, EMBASE, and Google Scholar. Selection criteria for articles were (1) publication in English between 1995 and 2014, (2) patients with GEP-NET, and (3) analysis of HRQoL, including mental health and psychological symptoms. Forty-nine studies met the inclusion criteria (31 clinical trials, 14 observational studies, and 4 developments of NET-specific HRQoL instruments). The scope and nature of the literature was diverse with 27 instruments used to measure aspects of HRQoL. EORTC QLQ-C30 was the most frequently used, in 38 of the 49 studies. Standardized measures revealed that in spite of generally good HRQoL, GEP-NET patients have specific psychological and physical complaints. The clinical benefit of somatostatin analogs and sunitinib has been clearly supported by HRQoL assessment. Improvement in HRQoL scores or symptom relief over time was also reported in 14 trials of peptide receptor radionuclide therapy, however the absence of randomized studies obviate definitive conclusions. We have also identified several unanswered questions that should be addressed in further research concerning chemotherapy, everolimus, surgery, local ablative therapies, and chemoembolization. Future research should incorporate GEP-NET-specific HRQoL instruments into phase III trials. This review may help both clinicians and researchers to select the most appropriate tools to assess changes in HRQoL in this population. Keywords Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) Health-related quality of life (HRQoL) Peptide receptor radionuclide therapy (PRRT) Quality of life (QoL) Questionnaires Surgery Locoregional therapy Somatostatin analogs (SSA) Chemotherapy Targeted therapy